Liquid Biopsy Market 112017

Liquid Biopsy Market: Rising Cases of Lung Cancer Fuelling Adoption of Liquid Biopsy Across the World: Global Industry Analysis (2012 - 2016) and Opportunity Assessment (2017 - 2027)

Ask The Analyst Customization Available Request Methodology

Market introduction

Liquid biopsy is an advanced cancer diagnostic test that uses biofluids such as blood, CSF, plasma and urine for detecting cancer. The test can also be used to detect cancer in the early stages. Liquid biopsy is a non-invasive diagnostic test that uses circulating nucleic acids, circulating tumour cells (CTC) and exosomes as a biomarker for the diagnosis of cancer. In the body, the aforementioned biomarkers are released into different body fluids by cancer cells. The test requires blood, urine and cerebral spinal fluid (CSF) samples for diagnosis of various cancers. Among all samples, blood sample is widely used for diagnosis of various cancers such as lung cancer, breast cancer and leukemia. Urine and CSF samples are used for the diagnosis of prostate cancer and brain cancer respectively. In this report, we have considered revenue generation by liquid biopsy test kits and liquid biopsy tests as a whole.

Factors impacting market revenue growth

The demand for liquid biopsy is expected to surge in the coming years owing to the increasing inclination of patients towards non-invasive diagnostic procedures, increasing demand from pharmaceutical and biotechnology companies and rising preference by oncologists for liquid biopsy. Increasing prevalence of lung cancer, growing number of product launches and increasing adoption of personalised medicine is expected to drive revenue growth of the liquid biopsy market.

Market forecast by disease indication

Based on disease indication, the global liquid biopsy market has been segmented into lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, colorectal cancer, leukemia, and others. Clinics in North America are opting for advanced treatment therapies leading to the reduced risk of cancer recurrence. Increasing prevalence of lung and breast cancer is the main reason for the increasing revenue of liquid biopsy tests for lung and breast cancer respectively.

The lung cancer disease indication segment is expected to expand at a significant CAGR during the forecast period due to increasing prevalence of lung cancer around the world. Lung cancer is also anticipated to remain the most attractive disease indication segment in terms of revenue for players in the liquid biopsy market over the forecast period. Breast cancer segment is expected to be the second most lucrative market, with an attractiveness index of 1.6 during the forecast period. The breast cancer segment is expected to register a CAGR of 21.4% in terms of value over the forecast period, followed by the lung cancer segment with a value CAGR of 21.3% for the duration of the assessment period.

global liquid biopsy market

A few key trends governing the global liquid biopsy market

Increasing competition among established players for innovative molecular diagnostic tests in liquid biopsy is expected to drive growth of the global liquid biopsy market over the forecast period. Companies in the liquid biopsy test market are coming up with innovative molecular diagnostic tests, as these tests are gaining traction because of their non-invasive nature as compared to tissue biopsy methods for detecting cancer. Also, these tests provide a less-expensive way to monitor patients throughout the duration of the treatment.

Oncologists are increasingly inclined towards liquid biopsy tests to monitor the disease during the course of therapeutic treatment to detect any genetic mutation. An increasing number of companies in the liquid biopsy market are working to develop a series of tests for monitoring the disease progression. Also, there is an increasing trend for liquid biopsies being used for drug selection at the time of diagnosis, when biopsy tissue is not available or is not accessible. Additionally, liquid biopsies detect drug resistance, screening or early detection of cancer, development of companion diagnostics, determination of prognoses, and assessment of tumour heterogeneity.

Report Description & Structure

This Future Market Insights (FMI) report examines the global liquid biopsy market for the period 2017–2027. The primary objective of the report is to offer insights into developments in the liquid biopsy market that are effecting global businesses and enterprises. This report covers the global liquid biopsy market performance in terms of revenue contribution from various segments. The report also includes in-depth analysis of key trends, drivers, restraints and opportunities, which are likely to influence growth of the global liquid biopsy market. Impact analysis of key growth drivers and restraints are included in this report to better equip clients with crystal clear decision-making insights. The liquid biopsy market report begins with an overview of the market and key definitions. This section also underlines factors influencing revenue growth of the liquid biopsy market along with a detailing of the key trends, drivers, restraints, and opportunities. Furthermore, FMI provides a competitive landscape of the top companies operating in the global liquid biopsy market along with their strategic developments.

Market Segmentation

Biomarker Type

Sample Type

End User

Disease Indication

Region

  • CTCs (Circulating tumour Cells)

  • ctNA (Circulating tumour Nucleic Acids)

  • Exosomes

  • Blood

  • Urine

  • Others (Plasma, Saliva, CSF)

  • Hospitals

  • Cancer Institutes

  • Academic Institutes

  • Diagnostic Centers

  • Lung Cancer

  • Gastrointestinal Cancer

  • Prostate Cancer

  • Breast Cancer

  • Colorectal Cancer

  • Leukemia

  • Others

  • North America

  • Latin America

  • Western Europe

  • Eastern Europe

  • APEJ

  • Japan

  • MEA

The next few sections of the report analyse the global liquid biopsy market based on biomarker type, sample type, disease indication, and end user and present a comprehensive forecast in terms of value for the next 10 years. The next section of the report highlights the growth trends of the liquid biopsy market by region. It provides a market outlook for 2017–2027 and sets the forecast within the context of the global liquid biopsy market. The study discusses key regional trends contributing to the growth of the liquid biopsy market worldwide, as well as analyses the extent to which drivers are influencing this market in each region.

In the final section of the report on the global liquid biopsy market, a detailed competitive landscape is included to provide report audiences with a dashboard view of the leading market players along with information on the key differentiators among the competitor firms. Detailed company profiles presented in this section include company-specific long-term and short-term strategies, key offerings and recent developments in the global liquid biopsy market.

Research Methodology

While forecasting the revenue estimations for the global liquid biopsy market, we have taken into consideration the year-on-year growth to understand the predictability of the market and to identify the right growth opportunities in the global liquid biopsy market. Another key feature of this report is the analysis of the different market segments in terms of absolute dollar opportunity. This is traditionally overlooked while forecasting the market. However, absolute dollar opportunity analysis is critical for assessing the level of opportunity that a provider can look to achieve, as well as to identify potential resources from a sales and delivery perspective in the global liquid biopsy market.

Liquid Biopsy Market 112017 Reports - Table of Contents

1. Executive Summary

1.1. Overview

1.2. Market Analysis

1.3. FMI Analysis and Recommendations

2. Market Introduction

2.1. Market Taxonomy

2.2. Market Definition

3. Liquid Biopsy Market View Point Analysis 

3.1. Macro-Economic Factors

3.2. Opportunity Analysis

3.3. Demand Side Drives

3.4. Supply Side Drivers

3.5. Restraints

3.6. Trends

3.7. Epidemiology Assessment

3.8. Reimbursement Scenario

3.9. Pipeline Assessment

3.10. Strategies and Price Impact

3.11. Case Study

4. North America Liquid Biopsy Market Analysis 2012–2016 and Forecast 2017–2027

4.1. Introduction

4.2. Regional Market Trends

4.3. Historical Market Size (US$ Mn) Trend Analysis By Country, 2012–2016

4.3.1. U.S.

4.3.2. Canada

4.4. Market Size (US$ Mn) Forecast By Country, 2017–2027

4.4.1. U.S.

4.4.2. Canada

4.5. Historical Market Size (US$ Mn) Trend Analysis By Biomarker Type, 2012–2016

4.5.1. CTC (Circulating Tumor Cells)

4.5.2. ctNA (Circulating Tumor Nucliec Acids)

4.5.3. Exosomes 

4.6. Market Size (US$ Mn) Forecast By Biomarker Type, 2017–2027

4.6.1. CTC (Circulating Tumor Cells)

4.6.2. ctNA (Circulating Tumor Nucliec Acids)

4.6.3. Exosomes 

4.7. Historical Market Size (US$ Mn) Trend Analysis By Sample Type, 2012–2016

4.7.1. Blood

4.7.2. Urine

4.7.3. Others

4.8. Market Size (US$ Mn) Forecast By Sample Type, 2017–2027

4.8.1. Blood

4.8.2. Urine

4.8.3. Others

4.9. Historical Market Size (US$ Mn) Trend Analysis By Disease Indication, 2012–2016

4.9.1. Lung Cancer

4.9.2. Gastrointestinal Cancer

4.9.3. Prostate Cancer

4.9.4. Breast Cancer

4.9.5. Colorectal Cancer

4.9.6. Leukemia

4.9.7. Others

4.10. Market Size (US$ Mn) Forecast By Disease Indication, 2017–2027

4.10.1. Lung Cancer

4.10.2. Gastrointestinal Cancer

4.10.3. Prostate Cancer

4.10.4. Breast Cancer

4.10.5. Colorectal Cancer

4.10.6. Leukemia

4.10.7. Others

4.11. Historical Market Size (US$ Mn) Trend Analysis By End User, 2012–2016

4.11.1. Hospitals

4.11.2. Cancer Institutes

4.11.3. Academic Institutes

4.11.4. Diagnostic Centers 

4.12. Market Size (US$ Mn) Forecast By End User, 2017–2027

4.12.1. Hospitals

4.12.2. Cancer Institutes

4.12.3. Academic Institutes

4.12.4. Diagnostic Centers 

4.13. Drivers and Restraints: Impact Analysis

4.14. Market Attractiveness Analysis

4.14.1. By Country

4.14.2. By Biomarker Type  

4.14.3. By Sample Type  

4.14.4. By Disease Indication

4.14.5. By End User

5. Latin America Liquid Biopsy Market Analysis 2012–2016 and Forecast 2017–2027

5.1. Introduction

5.2. Regional Market Trends

5.3. Historical Market Size (US$ Mn) Trend Analysis By Country, 2012–2016

5.3.1. Brazil

5.3.2. Mexico

5.3.3. Rest of Latin America

5.4. Market Size (US$ Mn) Forecast By Country, 2017–2027

5.4.1. Brazil

5.4.2. Mexico

5.4.3. Rest of Latin America

5.5. Historical Market Size (US$ Mn) Trend Analysis By Biomarker Type, 2012–2016

5.5.1. CTC (Circulating Tumor Cells)

5.5.2. ctNA (Circulating Tumor Nucliec Acids)

5.5.3. Exosomes 

5.6. Market Size (US$ Mn) Forecast By Biomarker Type, 2017–2027

5.6.1. CTC (Circulating Tumor Cells)

5.6.2. ctNA (Circulating Tumor Nucliec Acids)

5.6.3. Exosomes 

5.7. Historical Market Size (US$ Mn) Trend Analysis By Sample Type, 2012–2016

5.7.1. Blood

5.7.2. Urine

5.7.3. Others

5.8. Market Size (US$ Mn) Forecast By Sample Type, 2017–2027

5.8.1. Blood

5.8.2. Urine

5.8.3. Others

5.9. Historical Market Size (US$ Mn) Trend Analysis By Disease Indication, 2012–2016

5.9.1. Lung Cancer

5.9.2. Gastrointestinal Cancer

5.9.3. Prostate Cancer

5.9.4. Breast Cancer

5.9.5. Colorectal Cancer

5.9.6. Leukemia

5.9.7. Others

5.10. Market Size (US$ Mn) Forecast By Disease Indication, 2017–2027

5.10.1. Lung Cancer

5.10.2. Gastrointestinal Cancer

5.10.3. Prostate Cancer

5.10.4. Breast Cancer

5.10.5. Colorectal Cancer

5.10.6. Leukemia

5.10.7. Others

5.11. Historical Market Size (US$ Mn) Trend Analysis By End User, 2012–2016

5.11.1. Hospitals

5.11.2. Cancer Institutes

5.11.3. Academic Institutes

5.11.4. Diagnostic Centers 

5.12. Market Size (US$ Mn) Forecast By End User, 2017–2027

5.12.1. Hospitals

5.12.2. Cancer Institutes

5.12.3. Academic Institutes

5.12.4. Diagnostic Centers 

5.13. Drivers and Restraints: Impact Analysis

5.14. Market Attractiveness Analysis

5.14.1. By Country

5.14.2. By Biomarker Type  

5.14.3. By Sample Type  

5.14.4. By Disease Indication

5.14.5. By End User

6. Western Europe Liquid Biopsy Market Analysis 2012–2016 and Forecast 2017–2027

6.1. Introduction

6.2. Regional Market Trends

6.3. Historical Market Size (US$ Mn) Trend Analysis By Country, 2012–2016

6.3.1. U.K.

6.3.2. Germany

6.3.3. France

6.3.4. Spain

6.3.5. Italy

6.3.6. NORDIC

6.3.7. BENELUX

6.3.8. Rest of Western Europe

6.4. Market Size (US$ Mn) Forecast By Country, 2017–2027

6.4.1. U.K.

6.4.2. Germany

6.4.3. France

6.4.4. Spain

6.4.5. Italy

6.4.6. NORDIC

6.4.7. BENELUX

6.4.8. Rest of Western Europe

6.5. Historical Market Size (US$ Mn) Trend Analysis By Biomarker Type, 2012–2016

6.5.1. CTC (Circulating Tumor Cells)

6.5.2. ctNA (Circulating Tumor Nucliec Acids)

6.5.3. Exosomes 

6.6. Market Size (US$ Mn) Forecast By Biomarker Type, 2017–2027

6.6.1. CTC (Circulating Tumor Cells)

6.6.2. ctNA (Circulating Tumor Nucliec Acids)

6.6.3. Exosomes 

6.7. Historical Market Size (US$ Mn) Trend Analysis By Sample Type, 2012–2016

6.7.1. Blood

6.7.2. Urine

6.7.3. Others

6.8. Market Size (US$ Mn) Forecast By Sample Type, 2017–2027

6.8.1. Blood

6.8.2. Urine

6.8.3. Others

6.9. Historical Market Size (US$ Mn) Trend Analysis By Disease Indication, 2012–2016

6.9.1. Lung Cancer

6.9.2. Gastrointestinal Cancer

6.9.3. Prostate Cancer

6.9.4. Breast Cancer

6.9.5. Colorectal Cancer

6.9.6. Leukemia

6.9.7. Others

6.10. Market Size (US$ Mn) Forecast By Disease Indication, 2017–2027

6.10.1. Lung Cancer

6.10.2. Gastrointestinal Cancer

6.10.3. Prostate Cancer

6.10.4. Breast Cancer

6.10.5. Colorectal Cancer

6.10.6. Leukemia

6.10.7. Others

6.11. Historical Market Size (US$ Mn) Trend Analysis By End User, 2012–2016

6.11.1. Hospitals

6.11.2. Cancer Institutes

6.11.3. Academic Institutes

6.11.4. Diagnostic Centers 

6.12. Market Size (US$ Mn) Forecast By End User, 2017–2027

6.12.1. Hospitals

6.12.2. Cancer Institutes

6.12.3. Academic Institutes

6.12.4. Diagnostic Centers 

6.13. Drivers and Restraints: Impact Analysis

6.14. Market Attractiveness Analysis

6.14.1. By Country

6.14.2. By Biomarker Type  

6.14.3. By Sample Type  

6.14.4. By Disease Indication

6.14.5. By End User

7. Eastern Europe Liquid Biopsy Market Analysis 2012–2016 and Forecast 2017–2027

7.1. Introduction

7.2. Regional Market Trends

7.3. Historical Market Size (US$ Mn) Trend Analysis By Country, 2012–2016

7.3.1. Russia

7.3.2. Poland

7.3.3. Rest of Eastern Europe

7.4. Market Size (US$ Mn) Forecast By Country, 2017–2027

7.4.1. Russia

7.4.2. Poland

7.4.3. Rest of Eastern Europe

7.5. Historical Market Size (US$ Mn) Trend Analysis By Biomarker Type, 2012–2016

7.5.1. CTC (Circulating Tumor Cells)

7.5.2. ctNA (Circulating Tumor Nucliec Acids)

7.5.3. Exosomes 

7.6. Market Size (US$ Mn) Forecast By Biomarker Type, 2017–2027

7.6.1. CTC (Circulating Tumor Cells)

7.6.2. ctNA (Circulating Tumor Nucliec Acids)

7.6.3. Exosomes 

7.7. Historical Market Size (US$ Mn) Trend Analysis By Sample Type, 2012–2016

7.7.1. Blood

7.7.2. Urine

7.7.3. Others

7.8. Market Size (US$ Mn) Forecast By Sample Type, 2017–2027

7.8.1. Blood

7.8.2. Urine

7.8.3. Others

7.9. Historical Market Size (US$ Mn) Trend Analysis By Disease Indication, 2012–2016

7.9.1. Lung Cancer

7.9.2. Gastrointestinal Cancer

7.9.3. Prostate Cancer

7.9.4. Breast Cancer

7.9.5. Colorectal Cancer

7.9.6. Leukemia

7.9.7. Others

7.10. Market Size (US$ Mn) Forecast By Disease Indication, 2017–2027

7.10.1. Lung Cancer

7.10.2. Gastrointestinal Cancer

7.10.3. Prostate Cancer

7.10.4. Breast Cancer

7.10.5. Colorectal Cancer

7.10.6. Leukemia

7.10.7. Others

7.11. Historical Market Size (US$ Mn) Trend Analysis By End User, 2012–2016

7.11.1. Hospitals

7.11.2. Cancer Institutes

7.11.3. Academic Institutes

7.11.4. Diagnostic Centers 

7.12. Market Size (US$ Mn) Forecast By End User, 2017–2027

7.12.1. Hospitals

7.12.2. Cancer Institutes

7.12.3. Academic Institutes

7.12.4. Diagnostic Centers 

7.13. Drivers and Restraints: Impact Analysis

7.14. Market Attractiveness Analysis

7.14.1. By Country

7.14.2. By Biomarker Type  

7.14.3. By Sample Type  

7.14.4. By Disease Indication

7.14.5. By End User

8. Asia Pacific excluding Japan Liquid Biopsy Market Analysis 2012–2016 and Forecast 2017–2027

8.1. Introduction

8.2. Regional Market Trends

8.3. Historical Market Size (US$ Mn) Trend Analysis By Country, 2012–2016

8.3.1. China

8.3.2. India

8.3.3. Australia and New Zealand

8.3.4. ASEAN

8.3.5. Rest of APEJ

8.4. Market Size (US$ Mn) Forecast By Country, 2017–2027

8.4.1. China

8.4.2. India

8.4.3. Australia and New Zealand

8.4.4. ASEAN

8.4.5. Rest of APEJ

8.5. Historical Market Size (US$ Mn) Trend Analysis By Biomarker Type, 2012–2016

8.5.1. CTC (Circulating Tumor Cells)

8.5.2. ctNA (Circulating Tumor Nucliec Acids)

8.5.3. Exosomes 

8.6. Market Size (US$ Mn) Forecast By Biomarker Type, 2017–2027

8.6.1. CTC (Circulating Tumor Cells)

8.6.2. ctNA (Circulating Tumor Nucliec Acids)

8.6.3. Exosomes 

8.7. Historical Market Size (US$ Mn) Trend Analysis By Sample Type, 2012–2016

8.7.1. Blood

8.7.2. Urine

8.7.3. Others

8.8. Market Size (US$ Mn) Forecast By Sample Type, 2017–2027

8.8.1. Blood

8.8.2. Urine

8.8.3. Others

8.9. Historical Market Size (US$ Mn) Trend Analysis By Disease Indication, 2012–2016

8.9.1. Lung Cancer

8.9.2. Gastrointestinal Cancer

8.9.3. Prostate Cancer

8.9.4. Breast Cancer

8.9.5. Colorectal Cancer

8.9.6. Leukemia

8.9.7. Others

8.10. Market Size (US$ Mn) Forecast By Disease Indication, 2017–2027

8.10.1. Lung Cancer

8.10.2. Gastrointestinal Cancer

8.10.3. Prostate Cancer

8.10.4. Breast Cancer

8.10.5. Colorectal Cancer

8.10.6. Leukemia

8.10.7. Others

8.11. Historical Market Size (US$ Mn) Trend Analysis By End User, 2012–2016

8.11.1. Hospitals

8.11.2. Cancer Institutes

8.11.3. Academic Institutes

8.11.4. Diagnostic Centers 

8.12. Market Size (US$ Mn) Forecast By End User, 2017–2027

8.12.1. Hospitals

8.12.2. Cancer Institutes

8.12.3. Academic Institutes

8.12.4. Diagnostic Centers 

8.13. Drivers and Restraints: Impact Analysis

8.14. Market Attractiveness Analysis

8.14.1. By Country

8.14.2. By Biomarker Type  

8.14.3. By Sample Type  

8.14.4. By Disease Indication

8.14.5. By End User

9. Japan Liquid Biopsy Market Analysis 2012–2016 and Forecast 2017–2027

9.1. Introduction

9.2. Regional Market Trends

9.3. Historical Market Size (US$ Mn) Trend Analysis By Biomarker Type, 2012–2016

9.3.1. CTC (Circulating Tumor Cells)

9.3.2. ctNA (Circulating Tumor Nucliec Acids)

9.3.3. Exosomes 

9.4. Market Size (US$ Mn) Forecast By Biomarker Type, 2017–2027

9.4.1. CTC (Circulating Tumor Cells)

9.4.2. ctNA (Circulating Tumor Nucliec Acids)

9.4.3. Exosomes 

9.5. Historical Market Size (US$ Mn) Trend Analysis By Sample Type, 2012–2016

9.5.1. Blood

9.5.2. Urine

9.5.3. Others

9.6. Market Size (US$ Mn) Forecast By Sample Type, 2017–2027

9.6.1. Blood

9.6.2. Urine

9.6.3. Others

9.7. Historical Market Size (US$ Mn) Trend Analysis By Disease Indication, 2012–2016

9.7.1. Lung Cancer

9.7.2. Gastrointestinal Cancer

9.7.3. Prostate Cancer

9.7.4. Breast Cancer

9.7.5. Colorectal Cancer

9.7.6. Leukemia

9.7.7. Others

9.8. Market Size (US$ Mn) Forecast By Disease Indication, 2017–2027

9.8.1. Lung Cancer

9.8.2. Gastrointestinal Cancer

9.8.3. Prostate Cancer

9.8.4. Breast Cancer

9.8.5. Colorectal Cancer

9.8.6. Leukemia

9.8.7. Others

9.9. Historical Market Size (US$ Mn) Trend Analysis By End User, 2012–2016

9.9.1. Hospitals

9.9.2. Cancer Institutes

9.9.3. Academic Institutes

9.9.4. Diagnostic Centers 

9.10. Market Size (US$ Mn) Forecast By End User, 2017–2027

9.10.1. Hospitals

9.10.2. Cancer Institutes

9.10.3. Academic Institutes

9.10.4. Diagnostic Centers 

9.11. Drivers and Restraints: Impact Analysis

9.12. Market Attractiveness Analysis

9.12.1. By Biomarker Type  

9.12.2. By Sample Type  

9.12.3. By Disease Indication

9.12.4. By End User

10. Middle East & Africa Liquid Biopsy Market Analysis 2012–2016 and Forecast 2017–2027

10.1. Introduction

10.2. Historical Market Size (US$ Mn) Trend Analysis By Country, 2012–2016

10.2.1. GCC Countries

10.2.2. South Africa

10.2.3. Rest of MEA

10.3. Market Size (US$ Mn) Forecast By Country, 2017–2027

10.3.1. GCC Countries

10.3.2. South Africa

10.3.3. Rest of MEA

10.4. Historical Market Size (US$ Mn) Trend Analysis By Biomarker Type, 2012–2016

10.4.1. CTC (Circulating Tumor Cells)

10.4.2. ctNA (Circulating Tumor Nucliec Acids)

10.4.3. Exosomes 

10.5. Market Size (US$ Mn) Forecast By Biomarker Type, 2017–2027

10.5.1. CTC (Circulating Tumor Cells)

10.5.2. ctNA (Circulating Tumor Nucliec Acids)

10.5.3. Exosomes 

10.6. Historical Market Size (US$ Mn) Trend Analysis By Sample Type, 2012–2016

10.6.1. Blood

10.6.2. Urine

10.6.3. Others

10.7. Market Size (US$ Mn) Forecast By Sample Type, 2017–2027

10.7.1. Blood

10.7.2. Urine

10.7.3. Others

10.8. Historical Market Size (US$ Mn) Trend Analysis By Disease Indication, 2012–2016

10.8.1. Lung Cancer

10.8.2. Gastrointestinal Cancer

10.8.3. Prostate Cancer

10.8.4. Breast Cancer

10.8.5. Colorectal Cancer

10.8.6. Leukemia

10.8.7. Others

10.9. Market Size (US$ Mn) Forecast By Disease Indication, 2017–2027

10.9.1. Lung Cancer

10.9.2. Gastrointestinal Cancer

10.9.3. Prostate Cancer

10.9.4. Breast Cancer

10.9.5. Colorectal Cancer

10.9.6. Leukemia

10.9.7. Others

10.10. Historical Market Size (US$ Mn) Trend Analysis By End User, 2012–2016

10.10.1. Hospitals

10.10.2. Cancer Institutes

10.10.3. Academic Institutes

10.10.4. Diagnostic Centers 

10.11. Market Size (US$ Mn) Forecast By End User, 2017–2027

10.11.1. Hospitals

10.11.2. Cancer Institutes

10.11.3. Academic Institutes

10.11.4. Diagnostic Centers 

10.12. Drivers and Restraints: Impact Analysis

10.13. Market Attractiveness Analysis

10.13.1. By Country

10.13.2. By Biomarker Type  

10.13.3. By Sample Type  

10.13.4. By Disease Indication

10.13.5. By End User

11. Competition Landscape

11.1. Competition Dashboard

11.2. Company Profiles (Details – Overview, Financials, Strategy, SWOT, Recent Developments)

11.2.1. Biocept, Inc.

11.2.2. Qiagen N.V.

11.2.3. Trovagene, Inc.

11.2.4. Johnson & Johnson

11.2.5. MDxHealth SA

11.2.6. Natera, Inc.

11.2.7. F. Hoffman-La Roche Ltd.

11.2.8. Silicon Biosystems S.p.A.

11.2.9. Pathway Genomics Corporation

11.2.10. Sysmex Corporation

12. Global Liquid Biopsy Market Analysis 2012–2016 and Forecast 2017–2027, By Region

12.1. Introduction/Key Findings

12.2. Historical Market Size (US$ Mn) Trend Analysis By Region, 2012–2016

12.2.1. North America

12.2.2. Latin America

12.2.3. Western Europe

12.2.4. Eastern Europe

12.2.5. Asia Pacific excluding Japan

12.2.6. Japan 

12.2.7. Middle East & Africa

12.3. Market Size (US$ Mn) Forecast By Region, 2017–2027

12.3.1. North America

12.3.2. Latin America

12.3.3. Western Europe

12.3.4. Eastern Europe

12.3.5. Asia Pacific excluding Japan

12.3.6. Japan 

12.3.7. Middle East & Africa

12.4. Market Attractiveness Analysis By Region

13. Global Pain Therapeutic Solutions Market Analysis 2012–2016 and Forecast 2017–2027, By Biomarker Type  

13.1. Introduction/Key Findings

13.2. Historical Market Size (US$ Mn) Trend Analysis By Biomarker Type, 2012–2016

13.2.1. CTC (Circulating Tumor Cells)

13.2.2. ctNA (Circulating Tumor Nucliec Acids)

13.2.3. Exosomes

13.3. Market Size (US$ Mn) Forecast By Biomarker Type, 2017–2027

13.3.1. CTC (Circulating Tumor Cells)

13.3.2. ctNA (Circulating Tumor Nucliec Acids)

13.3.3. Exosomes

13.4. Market Attractiveness Analysis By Biomarker Type  

14. Global Liquid Biopsy Market Analysis 2012–2016 and Forecast 2017–2027, By Sample Type  

14.1. Introduction/Key Findings

14.2. Historical Market Size (US$ Mn) Trend Analysis By Sample Type, 2012–2016

14.2.1. Blood

14.2.2. Urine

14.2.3. Others

14.3. Market Size (US$ Mn) Forecast By Sample Type  , 2017–2027

14.3.1. Blood

14.3.2. Urine

14.3.3. Others

14.4. Market Attractiveness Analysis By Sample Type  

15. Global Liquid Biopsy Market Analysis 2012–2016 and Forecast 2017–2027, By Disease Indication

15.1. Introduction/Key Findings

15.2. Historical Market Size (US$ Mn) Trend Analysis By Disease Indication, 2012–2016

15.2.1. Lung Cancer

15.2.2. Gastrointestinal Cancer

15.2.3. Prostate Cancer

15.2.4. Breast Cancer

15.2.5. Colorectal Cancer

15.2.6. Leukemia

15.2.7. Others

15.3. Market Size (US$ Mn) Forecast By Disease Indication, 2017–2027

15.3.1. Lung Cancer

15.3.2. Gastrointestinal Cancer

15.3.3. Prostate Cancer

15.3.4. Breast Cancer

15.3.5. Colorectal Cancer

15.3.6. Leukemia

15.3.7. Others

15.4. Market Attractiveness Analysis By Disease Indication

16. Global Liquid Biopsy Market Analysis 2012–2016 and Forecast 2017–2027, By End User

16.1. Introduction/Key Findings

16.2. Historical Market Size (US$ Mn) Trend Analysis By End User, 2012–2016

16.2.1. Hospitals

16.2.2. Cancer Institutes

16.2.3. Academic Institutes

16.2.4. Diagnostic Centers

16.3. Market Size (US$ Mn) Forecast By End User, 2017–2027

16.3.1. Hospitals

16.3.2. Cancer Institutes

16.3.3. Academic Institutes

16.3.4. Diagnostic Centers

16.4. Market Attractiveness Analysis By End User

17. Global Liquid Biopsy Market Analysis 2012–2016 and Forecast 2017–2027

17.1. Market Size and Y-o-Y Growth

17.2. Absolute $ Opportunity

18. Assumptions and Acronyms Used

19. Research Methodology

Liquid Biopsy Market 112017 Reports - List of Tables

Table 01: North America Liquid Biopsy Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Country

Table 02: North America Liquid Biopsy Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Biomarker Type

Table 03: North America Liquid Biopsy Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Sample Type

Table 04: North America Liquid Biopsy Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Disease Indication

Table 05: North America Liquid Biopsy Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By End User

Table 06: Latin America Liquid Biopsy Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Country

Table 07: Latin America Liquid Biopsy Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Biomarker Type

Table 08: Latin America Liquid Biopsy Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Sample Type

Table 09: Latin America Liquid Biopsy Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Disease Indication

Table 10: Latin America Liquid Biopsy Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By End User

Table 11: Western Europe Liquid Biopsy Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Country

Table 12: Western Europe Liquid Biopsy Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Biomarker Type

Table 13: Western Europe Liquid Biopsy Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Sample Type

Table 14: Western Europe Liquid Biopsy Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Disease Indication

Table 15: Western Europe Liquid Biopsy Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By End User

Table 16: Eastern Europe Liquid Biopsy Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Country

Table 17: Eastern Europe Liquid Biopsy Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Biomarker Type

Table 18: Eastern Europe Liquid Biopsy Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Sample Type

Table 19: Eastern Europe Liquid Biopsy Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Disease Indication

Table 20: Eastern Europe Liquid Biopsy Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By End User

Table 21: APEJ Liquid Biopsy Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Country

Table 22: APEJ Liquid Biopsy Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Biomarker Type

Table 23: APEJ Liquid Biopsy Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Sample Type

Table 24: APEJ Liquid Biopsy Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Disease Indication

Table 25: APEJ Liquid Biopsy Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By End User

Table 26: Japan Liquid Biopsy Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Biomarker Type

Table 27: Japan Liquid Biopsy Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Sample Type

Table 28: Japan Liquid Biopsy Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Disease Indication

Table 29: Japan Liquid Biopsy Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By End User

Table 30: MEA Liquid Biopsy Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Country

Table 31: MEA Liquid Biopsy Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Biomarker Type

Table 32: MEA Liquid Biopsy Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Sample Type

Table 33: MEA Liquid Biopsy Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Disease Indication

Table 34: MEA Liquid Biopsy Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By End User

Table 35: Global Liquid Biopsy Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Region

Table 36: Global Liquid Biopsy Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Biomarker Type

Table 37: Global Liquid Biopsy Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Sample Type

Table 38: Global Liquid Biopsy Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Disease Indication

Table 39: Global Liquid Biopsy Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By End User

Liquid Biopsy Market 112017 Reports - List of Figures

Figure 1: Global Liquid Biopsy Market Value Share By Biomarker Type (2016A)

Figure 2: Global Liquid Biopsy Market Value Share By Sample Type (2016A)

Figure 3: Global Liquid Biopsy Market Value Share By Disease Indication (2016A)

Figure 4: Global Liquid Biopsy Market Value Share By End User (2016A)

Figure 5: Global Liquid Biopsy Market Value Share By Region (2016A)

Figure 6: North America Liquid Biopsy Market Value Share By Biomarker Type (2017E)

Figure 7: North America Liquid Biopsy Market Value Share By Sample Type (2017E)

Figure 8: North America Liquid Biopsy Market Value Share By Disease Indication (2017E)

Figure 9: North America Liquid Biopsy Market Value Share By End User (2017E)

Figure 10: North America Liquid Biopsy Market Value Share By Region (2017E)

Figure 11: North America Liquid Biopsy Market Size Analysis, 2012-2016

Figure 12: North America Liquid Biopsy Market Forecast, 2017–2027

Figure 13: U.S. Liquid Biopsy Market Size (US$ Mn) Analysis, 2012–2016

Figure 14: U.S. Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%), 2017–2027

Figure 15: Canada Liquid Biopsy Market Size (US$ Mn) Analysis, 2012–2016

Figure 16: Canada Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%), 2017–2027

Figure 17: North America Liquid Biopsy Market Attractiveness Analysis, By Biomarker Type, 2017–2027 

Figure 18: North America Liquid Biopsy Market Attractiveness Analysis, By Sample Type, 2017–2027 

Figure 19: North America Liquid Biopsy Market Attractiveness Analysis, By End User, 2017–2027 

Figure 20: North America Liquid Biopsy Market Attractiveness Analysis, By Disease Indication, 2017–2027 

Figure 21: North America Liquid Biopsy Market Attractiveness Analysis, By Region, 2017–2027 

Figure 22: Latin America Liquid Biopsy Market Value Share By Biomarker Type (2017E)

Figure 23: Latin America Liquid Biopsy Market Value Share By Sample Type (2017E)

Figure 24: Latin America Liquid Biopsy Market Value Share By Disease Indication (2017E)

Figure 25: Latin America Liquid Biopsy Market Value Share By End User (2017E)

Figure 26: Latin America Liquid Biopsy Market Value Share By Region (2017E)

Figure 27: Latin America Liquid Biopsy Market Size Analysis, 2012-2016

Figure 28: Latin America Liquid Biopsy Market Forecast, 2017–2027

Figure 29: Brazil Liquid Biopsy Market Size (US$ Mn) Analysis, 2012–2016

Figure 30: Brazil Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%), 2017–2027

Figure 31: Mexico Liquid Biopsy Market Size (US$ Mn) Analysis, 2012–2016

Figure 32: Mexico Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%), 2017–2027

Figure 33: Rest of Latin America Liquid Biopsy Market Size (US$ Mn) Analysis, 2012–2016

Figure 34: Rest of Latin America Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%), 2017–2027

Figure 35: Latin America Liquid Biopsy Market Attractiveness Analysis, By Biomarker Type, 2017–2027 

Figure 36: Latin America Liquid Biopsy Market Attractiveness Analysis, By Sample Type, 2017–2027 

Figure 37: Latin America Liquid Biopsy Market Attractiveness Analysis, By End User, 2017–2027 

Figure 38: Latin America Liquid Biopsy Market Attractiveness Analysis, By Disease Indication, 2017–2027 

Figure 39: Latin America Liquid Biopsy Market Attractiveness Analysis, By Region, 2017–2027 

Figure 40: Western Europe Liquid Biopsy Market Value Share By Biomarker Type (2017E)

Figure 41: Western Europe Liquid Biopsy Market Value Share By Sample Type (2017E)

Figure 42: Western Europe Liquid Biopsy Market Value Share By Disease Indication (2017E)

Figure 43: Western Europe Liquid Biopsy Market Value Share By End User (2017E)

Figure 44: Western Europe Liquid Biopsy Market Value Share By Region (2017E)

Figure 45: Western Europe Liquid Biopsy Market Size Analysis, 2012-2016

Figure 46: Western Europe Liquid Biopsy Market Forecast, 2017–2027

Figure 47: U.K. Liquid Biopsy Market Size (US$ Mn) Analysis, 2012–2016 

Figure 48: U.K. Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%), 2017–2027

Figure 49: Germany Liquid Biopsy Market Size (US$ Mn) Analysis, 2012–2016

Figure 50: Germany Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%), 2017–2027

Figure 51: France Liquid Biopsy Market Size (US$ Mn) Analysis, 2012–2016

Figure 52: France Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%), 2017–2027

Figure 53: Spain Liquid Biopsy Market Size (US$ Mn) Analysis, 2012–2016

Figure 54: Spain Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%), 2017–2027

Figure 55: Italy Liquid Biopsy Market Size (US$ Mn) Analysis, 2012–2016

Figure 56: Italy Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%), 2017–2027

Figure 57: Nordic Liquid Biopsy Market Size (US$ Mn) Analysis, 2012–2016

Figure 58: Nordic Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%), 2017–2027

Figure 59: BENELUX Liquid Biopsy Market Size (US$ Mn) Analysis, 2012–2016

Figure 60: BENELUX Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%), 2017–2027

Figure 61: Rest of Western Europe Liquid Biopsy Market Size (US$ Mn) Analysis, 2012–2016

Figure 62: Rest of Western Europe Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%), 2017–2027

Figure 63: Western Europe Liquid Biopsy Market Attractiveness Analysis, By Biomarker Type, 2017–2027 

Figure 64: Western Europe Liquid Biopsy Market Attractiveness Analysis, By Sample Type, 2017–2027 

Figure 65: Western Europe Liquid Biopsy Market Attractiveness Analysis, By End User, 2017–2027 

Figure 66: Western Europe Liquid Biopsy Market Attractiveness Analysis, By Disease Indication, 2017–2027 

Figure 67: Western Europe Liquid Biopsy Market Attractiveness Analysis, By Region, 2017–2027 

Figure 68: Eastern Europe Liquid Biopsy Market Value Share By Biomarker Type (2017E)

Figure 69: Eastern Europe Liquid Biopsy Market Value Share By Sample Type (2017E)

Figure 70: Eastern Europe Liquid Biopsy Market Value Share By Disease Indication (2017E)

Figure 71: Eastern Europe Liquid Biopsy Market Value Share By End User (2017E)

Figure 72: Eastern Europe Liquid Biopsy Market Value Share By Region (2017E)

Figure 73: Eastern Europe Liquid Biopsy Market Size Analysis, 2012-2016

Figure 74: Eastern Europe Liquid Biopsy Market Forecast, 2017–2027

Figure 75: Russia Liquid Biopsy Market Size (US$ Mn) Analysis, 2012–2016

Figure 76: Russia Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%), 2017–2027

Figure 77: Poland Liquid Biopsy Market Size (US$ Mn) Analysis, 2012–2016

Figure 78: Poland Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%), 2017–2027

Figure 79: Rest of Eastern Europe Liquid Biopsy Market Size (US$ Mn) Analysis, 2012–2016

Figure 80: Rest of Eastern Europe Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%), 2017–2027

Figure 81: Eastern Europe Liquid Biopsy Market Attractiveness Analysis, By Biomarker Type, 2017–2027 

Figure 82: Eastern Europe Liquid Biopsy Market Attractiveness Analysis, By Sample Type, 2017–2027 

Figure 83: Eastern Europe Liquid Biopsy Market Attractiveness Analysis, By End User, 2017–2027 

Figure 84: Eastern Europe Liquid Biopsy Market Attractiveness Analysis, By Disease Indication, 2017–2027 

Figure 85: Eastern Europe Liquid Biopsy Market Attractiveness Analysis, By Region, 2017–2027 

Figure 86: APEJ Liquid Biopsy Market Value Share By Biomarker Type (2017E)

Figure 87: APEJ Liquid Biopsy Market Value Share By Sample Type (2017E)

Figure 88: APEJ Liquid Biopsy Market Value Share By Disease Indication (2017E)

Figure 89: APEJ Liquid Biopsy Market Value Share By End User (2017E)

Figure 90: APEJ Liquid Biopsy Market Value Share By Region (2017E)

Figure 91: APEJ Liquid Biopsy Market Size Analysis, 2012-2016

Figure 92: APEJ Liquid Biopsy Market Forecast, 2017–2027

Figure 93: China Liquid Biopsy Market Size (US$ Mn) Analysis, 2012–2016

Figure 94: China Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%), 2017–2027

Figure 95: India Liquid Biopsy Market Size (US$ Mn) Analysis, 2012–2016

Figure 96: India Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%), 2017–2027

Figure 97: Australia & New Zealand Liquid Biopsy Market Size (US$ Mn) Analysis, 2012–2016

Figure 98: Australia & New Zealand Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%), 2017–2027

Figure 99: ASEAN Liquid Biopsy Market Size (US$ Mn) Analysis, 2012–2016

Figure 100: ASEAN Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%), 2017–2027

Figure 101: Rest of APEJ Liquid Biopsy Market Size (US$ Mn) Analysis, 2012–2016

Figure 102: Rest of APEJ Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%), 2017–2027

Figure 103: APEJ Liquid Biopsy Market Attractiveness Analysis, By Biomarker Type, 2017–2027 

Figure 104: APEJ Liquid Biopsy Market Attractiveness Analysis, By Sample Type, 2017–2027 

Figure 105: APEJ Liquid Biopsy Market Attractiveness Analysis, By End User, 2017–2027 

Figure 106: APEJ Liquid Biopsy Market Attractiveness Analysis, By Disease Indication, 2017–2027 

Figure 107: APEJ Liquid Biopsy Market Attractiveness Analysis, By Region, 2017–2027 

Figure 108: Japan Liquid Biopsy Market Value Share By Biomarker Type (2017E)

Figure 109: Japan Liquid Biopsy Market Value Share By Sample Type (2017E)

Figure 110: Japan Liquid Biopsy Market Value Share By Disease Indication (2017E)

Figure 111: Japan Liquid Biopsy Market Value Share By End User (2017E)

Figure 112: Japan Liquid Biopsy Market Size Analysis, 2012-2016

Figure 113: Japan Liquid Biopsy Market Forecast, 2017–2027

Figure 114: Japan Liquid Biopsy Market Attractiveness Analysis, By Biomarker Type, 2017–2027 

Figure 115: Japan Liquid Biopsy Market Attractiveness Analysis, By Sample Type, 2017–2027 

Figure 116: Japan Liquid Biopsy Market Attractiveness Analysis, By End User, 2017–2027 

Figure 117: Japan Liquid Biopsy Market Attractiveness Analysis, By Disease Indication, 2017–2027 

Figure 118: MEA Liquid Biopsy Market Value Share By Biomarker Type (2017E)

Figure 119: MEA Liquid Biopsy Market Value Share By Sample Type (2017E)

Figure 120: MEA Liquid Biopsy Market Value Share By Disease Indication (2017E)

Figure 121: MEA Liquid Biopsy Market Value Share By End User (2017E)

Figure 122: MEA Liquid Biopsy Market Value Share By Region (2017E)

Figure 123: MEA Liquid Biopsy Market Size Analysis, 2012-2016

Figure 124: MEA Liquid Biopsy Market Forecast, 2017–2027

Figure 125: GCC Countries Liquid Biopsy Market Size (US$ Mn) Analysis, 2012–2016

Figure 126: GCC Countries Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%), 2017–2027

Figure 127: South Africa Liquid Biopsy Market Size (US$ Mn) Analysis, 2012–2016

Figure 128: South Africa Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%), 2017–2027

Figure 129: Rest of MEA Liquid Biopsy Market Size (US$ Mn) Analysis, 2012–2016

Figure 130: Rest of MEA Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%), 2017–2027

Figure 131: MEA Liquid Biopsy Market Attractiveness Analysis, By Biomarker Type, 2017–2027 

Figure 132: MEA Liquid Biopsy Market Attractiveness Analysis, By Sample Type, 2017–2027 

Figure 133: MEA Liquid Biopsy Market Attractiveness Analysis, By End User, 2017–2027 

Figure 134: MEA Liquid Biopsy Market Attractiveness Analysis, By Disease Indication, 2017–2027 

Figure 135: MEA Liquid Biopsy Market Attractiveness Analysis, By Region, 2017–2027 

Figure 136: Global Liquid Biopsy Market Y-o-Y Growth (%) Analysis 2017-2027, By Region

Figure 137: Global Liquid Biopsy Market Y-o-Y Growth (%) Analysis 2017-2027, By Region

Figure 138: Global Liquid Biopsy Market Y-o-Y Growth (%) Analysis 2017-2027, By Biomarker Type

Figure 139: Global Liquid Biopsy Market Y-o-Y Growth (%) Analysis 2017-2027, By Biomarker Type

Figure 140: Global Liquid Biopsy Market Y-o-Y Growth (%) Analysis 2017-2027, By Sample Type

Figure 141: Global Liquid Biopsy Market Y-o-Y Growth (%) Analysis 2017-2027, By Sample Type

Figure 142: Global Liquid Biopsy Market Y-o-Y Growth (%) Analysis 2017-2027, By Disease Indication

Figure 143: Global Liquid Biopsy Market Y-o-Y Growth (%) Analysis 2017-2027, By Disease Indication

Figure 144: Global Liquid Biopsy Market Y-o-Y Growth (%) Analysis 2017-2027, By End User

Figure 145: Global Liquid Biopsy Market Y-o-Y Growth (%) Analysis 2017-2027, By End User

Figure 146: Global Liquid Biopsy Market Value Analysis and Forecast, 2016–2027 (US$ Mn)

Figure 147: Global Liquid Biopsy Market Value (US$ Mn), 2012–2016

Figure 148: Global Liquid Biopsy Market Absolute $ Opportunity (US$ Mn), 2016–2027